




2025 Annual Report



OUR MISSION

OUR VISION

GUIDING PRINCIPLES

To save and improve lives by repurposing drugs

To create a world in which every drug is used to treat every disease it possibly can so no patient suffers while a cure hides in plain sight

Patient Impact: Patient impact is our top priority, and we are relentlessly focused on reducing suffering.

Efficient Innovation: We leverage existing data and AI to unlock new treatments from old drugs as efficiently as possible, maximizing impact per dollar and time.

Trust: We serve as a trusted source of information in a world where biases and financial incentives get in the way of patient impact.

All-vs.-All & End-to-End: We seek the best treatments across all drugs vs. all diseases and ensure we can reach patients in need.

Mission-Driven Collaboration: We can only fulfill our mission by working with partners and across the organization as one team.

Data- & Outcome-Driven: We make data-driven decisions, measure our success, and celebrate results, not activities.

Fixing the System: True to our nonprofit roots, we pursue treatments that are not profitable and go where pharma companies don't.

PRESIDENT'S LETTER	03
FIXING A BROKEN SYSTEM	04
FROM INSIGHTS TO IMPACT	06
SCALING OUR WORK	08
UNLOCKING HOPE	10
TRAILBLAZERS	12
SPOTLIGHTING OUR IMPACT	16
PARTNERING FOR CURES	18
THANK YOU	20
LOOKING AHEAD	21
OUR TEAM	22



Dear friends of Every Cure,

Fifteen years ago, my doctors told me, “We’ve tried everything. There’s nothing more we can do.”

I was 25 and a third-year medical student dedicated to becoming a doctor after my mom died of brain cancer when I became suddenly ill with Castleman disease, which caused my immune system to attack my organs. Five times in three years I nearly died. Once, a priest read me my last rites.

I was out of options. Creating a new drug would take 10-15 years and \$1 billion — time and money I didn’t have. My only hope was to find a drug that already existed.

I studied my blood in the lab and discovered that sirolimus — approved years earlier to suppress the immune system after kidney transplants — might help. It had never been tried for my disease, but I had nothing left to lose so I began taking it.

And I started to feel better. After nearly dying five times in 3.5 years, I have now been in remission for more than 11 years. During this time, I married the love of my life, had two beautiful children, and launched a lab at the University of Pennsylvania that has advanced 13 more repurposed drugs.

But I can’t stop thinking about all the people suffering from diseases with no treatments — and how existing drugs could help them.

That’s why we founded Every Cure. To save and improve lives by repurposing drugs. So no patient suffers when there’s a life-saving drug at their local pharmacy.

2025 has been a huge year for us. As you explore this report, you’ll read about how we harness the power of AI to identify repurposed drugs at an unprecedented rate and scale. You’ll get a deeper look at how our medical team evaluates promising treatments and advances them to patients. And you’ll meet some of the people whose lives were transformed by repurposed drugs — and who remind us why this work matters.

But we can’t do it alone. I hope you’ll join us by letting us know about promising repurposed drugs, donating to accelerate our impact, and raising awareness about the treatments we uncover.



Thank you for supporting our mission to unlock every cure so no patient is ever told “We’ve tried everything” — like I was — when there’s a cure on the pharmacy shelf.

Sincerely,

David Fajgenbaum,
MD, MBA, MSc
Co-Founder & President,
Every Cure



FIXING A BROKEN SYSTEM: UNCOVERING TREATMENTS HIDING IN PLAIN SIGHT



THE PROBLEM

Of the approximately 18,000 recognized diseases in the world today, only about 4,000 have FDA-approved medications. This means that more than 300 million people live with diseases that lack any treatment options, and millions more suffer from diseases for which existing drugs are ineffective, too expensive, or out of reach.

We know that many of the 4,000 existing FDA-approved medications have the potential to treat additional diseases — at a fraction of the time and cost of developing a new drug. However, 80% of FDA-approved drugs are off-patent and unprofitable, so companies are not incentivized to invest in further research to find additional uses for these drugs.

These drugs sit on pharmacy shelves, overlooked and ignored for additional diseases, while patients who could benefit from them continue to suffer.


THE SOLUTION

Every Cure harnesses the transformative power of AI to scan the world's biomedical knowledge and identify matches between existing medicines and diseases that need treatment. Our approach enables us to carry out broad searches and prioritize the most promising opportunities quickly and efficiently. Whereas it would take decades for teams of scientists to evaluate the potential for all drugs to treat all diseases, AI is able to generate tens of millions of predictions that can point our team to the most promising drug repurposing opportunities — in less than one day.

At Every Cure, we are committed to ensuring that existing medicines can reach every patient with every disease as quickly as possible.

Patients are waiting.

OUR THREE-STEP APPROACH



A FIRST-OF-ITS-KIND INITIATIVE

- Every Cure is unique in that we look across all drugs and all diseases to identify the best opportunities to save and improve lives.
- We ensure our work spans the entire process from discovery through reaching patients in need.
- We have built a team that can build a repurposing idea end-to-end to patients, and we invite patients, physicians, and researchers to share their ideas (at everycure.org/ideas) so we can help ensure they reach the finish line.
- We let the data point us to the best drug-disease matches and select opportunities where we can reduce the most suffering and maximize impact per dollar and time.
- We perform laboratory studies and clinical trials to evaluate their safety and efficacy and then work to ensure these medicines reach patients in need.

We are on a mission to unlock the full potential of every approved drug to treat every disease it possibly can. We have set the extraordinary goal of advancing repurposed treatments for 15-25 diseases by 2030. Beyond 2030, we will continue to discover and advance repurposing opportunities until every patient possible has benefited.

FROM INSIGHTS TO IMPACT: HOW WE'RE USING AI TO HELP US SAVE LIVES

Every Cure has pioneered a novel approach called computational pharmacophenomics™ and built an AI-powered drug repurposing platform to systematically unlock new uses for medicines. This platform sifts through the world's biomedical knowledge and evaluates the potential of all drugs and all diseases, and is steered by guidance from our Technical Advisory Council (TAC).

Unlike traditional drug repurposing, which begins with a single disease and searches for drugs that could be effective, or, more rarely, begins with a single drug and searches for diseases that could benefit from it, Every Cure evaluates and quantifies all drug-disease combinations to ensure we're always finding the opportunities with the highest repurposing potential.

The opportunities that are generated by the platform are reviewed by our medical team, which works closely with physicians, researchers, patient organizations, and others to assess the likelihood that the treatment will be effective, impactful, and feasible. Each month, they review more than 1,000 unique opportunities — and capture the feedback as structured data to be reincorporated into the platform to retrain and refine its ranking algorithms.

The most promising drug repurposing opportunities are presented to a Scientific Advisory Council (SAC) for advancement to lab studies, clinical trials, or dissemination.

One of TIME's Best Inventions of 2025

Every Cure's MATRIX platform was selected for this award, which recognizes groundbreaking inventions that change how we live.

TECH ADVISORY COUNCIL

Our AI work is guided by an experienced Technical Advisory Council, which is made up of leading experts in AI, data science, and biomedical research and includes the following leaders:

Matej Macak, PhD

Eric Horvitz, MD, PhD

Stuart Bailey, DPhil

Marinka Žitnik, PhD

Russ Altman, MD, PhD

Patricia Brennan, RN, PhD

We classify our promising drug repurposing opportunities into three categories:



Frontier Explorers

Drug repurposing opportunities with promising but limited evidence that need more laboratory investigation before they're ready to be studied in patients.



Clinical Gems

Drug repurposing opportunities with enough evidence suggesting they may work but that still require a few more questions to be addressed through clinical trials.



Unsung Heroes

Drug repurposing opportunities that have been shown to be effective but are not widely used due to various market failures.

Once a drug repurposing opportunity is endorsed by our Scientific Advisory Council, our medical team develops detailed plans for lab studies, clinical trials, and/or dissemination. Although each pair is identified through advanced data analysis and biomedical research or an insight from a physician or patient, clinical validation is always critical to translating it into a real-world treatment.

When clinical trials are necessary, Every Cure launches patient-centric trials that rigorously evaluate the safety and efficacy of treatments and generate the data needed to change clinical use. Specifically, they are intended to be able to encourage professional societies to update guidelines, patients to feel comfortable taking the medicine, physicians to prescribe it, payers to cover it, and, in some cases, the FDA to issue approval.



SCIENTIFIC ADVISORY COUNCIL

Our promising drug repurposing opportunities are evaluated by our Scientific Advisory Council, which is made up of physicians, researchers, and former regulators, and includes the following leaders:

Ruxandra Draghia-Akli, MD, PhD, Chair


David Fajgenbaum, MD, MBA, MSc

Stephen Groft, PharmD

Richard Riese, MD, PhD

Karin Von Balen, Pharm Sci

ZEROING IN ON TOP REPURPOSING TREATMENTS



**PATIENTS WITH DISEASES THAT
EVERY CURE IS TARGETING**




Courtesy Developmental
Medicine & Child Neurology and
Pediatric Review: International
Journal of Pediatric Research

SCALING OUR WORK: RAPIDLY EXPANDING OUR PIPELINE

In just one year of running our full pipeline — from AI predictions or expert-sourced ideas to deep evaluation — we have selected 9 drug repurposing programs for advancement that are at various stages of development.

These programs range from laboratory studies investigating the role that lidocaine injections may play in reducing recurrence of cancer after surgical excision to educating physicians about the role that anti-FRA antibodies may play in neurodevelopmental disorders.

In parallel to advancing these programs, we continue to review repurposing opportunities — more than 1,000 per month — to find additional high-potential drug repurposing treatments for advancement.



UNLOCKING HOPE: GETTING REPURPOSED DRUGS TO THE PEOPLE WHO NEED THEM

We know that identifying a promising repurposed drug — and proving it works — is only the first step. That is why we are launching an Impact Team.

The Impact Team will focus on ensuring patients can access the medicines we repurpose by collaborating with disease and patient organizations to update treatment guidelines; engaging with FDA and other regulators to explore innovative pathways; working with payers and insurance companies to inform them about effective treatments; reaching patients directly through marketing campaigns; and participating in medical and other conferences so physicians are aware of new treatments.

At Every Cure, we are singularly focused on saving and improving patients' lives by repurposing drugs and are committed to making sure every patient benefits from every treatment that could help them — as quickly as possible.

Since our co-founder and president, Dr. David Fajgenbaum, first repurposed sirolimus to save his life, he and his teams have advanced 13 more repurposed treatments for conditions such as idiopathic multicentric Castleman Disease, angiosarcoma, POEMS syndrome, unicentric Castleman disease, and DADA2 syndrome. Thousands of patients are alive today because of this scientific work and his team's and colleagues' efforts to reach patients with these treatments. And now repurposed treatments Every Cure is advancing are also saving and improving lives.

In Dr. Fajgenbaum's own words: "It's hard to express just how much it means to learn about patients we've helped go on to walk their children down the aisle on their wedding day, begin college, or tell their parents they love them for the first time. On the following pages, we've included a few of these stories from patients my team have been able to help over the last decade."



TRAILBLAZERS: THE HEROES BEHIND REPURPOSED MEDICINE

KAILA

Kaila was a 14-year-old girl when she became suddenly ill. Her family reached out to Dr. Fajgenbaum, who suggested a repurposed drug that saved her life. The below is Kaila's journey in her own words:

It started with stomach pain and vomiting. I thought maybe it was something I ate. But then I got so tired — like can't-get-out-of-bed tired. One day I just couldn't go to school. The next thing I knew, I was being rushed to the emergency room.

The doctors didn't know what was wrong. They ran scans, bloodwork, MRIs — but nothing made sense. Eventually, they told my parents: "You need to take her downtown to Lurie Children's Hospital." That's when things got really scary. My organs were starting to shut down. I was holding onto so much fluid my stomach looked nine months pregnant. I had tubes coming out of my chest to drain my lungs. I was barely recognizable — my arms so thin my bracelets slid right up past my elbows.

It took two months to finally get a diagnosis: idiopathic multicentric Castleman disease. It's this rare disorder where your immune system goes haywire and starts attacking your body. There's one FDA-approved drug for it, but it didn't work on me. Neither did the next one. Or the one after that. At some point, chemo became the only option. I lost my hair. I lost my energy. I lost track of how many nights I spent in the ICU. And still—nothing was working. My doctors started to run out of options.

That's when they reached out to Dr. Fajgenbaum and his team at the University of Pennsylvania. He told them about a brand-new lab finding his team had made — just weeks earlier. A cancer drug called Ruxolitinib might help. It had never been tried for my condition before. But they gave it to me. I remember the date: July 30, 2020. That was the day everything changed. For the first time, I got better. And I stayed better. I've been in remission ever since.

Now I'm a college sophomore, studying to become a nurse — so I can help other kids the way my nurses helped me. I know what it's like to be the one in the hospital bed. I want to be the one standing next to it, saying: "You're going to get through this. I did."



**“For the
first time,
I got better.
And I stayed
better.”**

MICHAEL

In 2016, Michael was told he had just three months to live. He had been diagnosed with metastatic angiosarcoma, a rare and aggressive cancer of the blood vessels, and all standard treatments had failed. With no options left, Michael turned to Dr. Fajgenbaum, who is his nephew.

Dr. Fajgenbaum began searching through published medical studies and came across a 2013 paper that had gone largely unnoticed. The study reported unusually high levels of a protein called PD-L1 in several angiosarcoma patients. So they had Michael's tumor tested — and it, too, showed high PD-L1 expression. This pointed to a possible treatment: pembrolizumab, a PD-1 inhibitor approved for other cancers but never before used for angiosarcoma.

With nothing to lose, Michael began treatment as the first patient with angiosarcoma that we're aware of to be treated with a PD-1 inhibitor. Incredibly, within days, his condition improved. Today, nine years later, he remains cancer-free.

Michael's recovery helped change the outlook for patients around the world diagnosed with his cancer. Today, pembrolizumab is included as a recommended therapy for angiosarcoma by the National Comprehensive Cancer Network and is used by physicians worldwide — off-label — for patients with this disease.

In Fall 2024, Michael walked his son down the aisle on his wedding day; in Fall 2025, he walked his daughter down the aisle on hers.



“Michael’s recovery helped change the outlook for patients around the world with his cancer.”

**“Within a week,
Joseph began
improving...
Today, he remains
in remission.”**

JOSEPH

In January 2024, Joseph was on life support with POEMS syndrome, a rare blood disorder that caused his vital organs to shut down. Liters of fluid were being drained from his abdomen and the treatments his doctors knew to try weren't working. His doctors told him the only thing left to decide was if he wanted to spend his final days in the hospital or on hospice at home. A stem cell transplant was his only hope, but he was too sick to receive one.

“I gave up,” he said. “I just thought the end was inevitable.”

Joseph’s girlfriend, Tara, reached out to Dr. Fajgenbaum, whom she had previously met at a conference. Over the weekend, he contacted Joseph’s doctor, suggesting that Joseph try a regimen of three drugs used for a condition similar to POEMS called multiple myeloma.

Within a week, Joseph began improving. Four months later, he was healthy enough to receive a stem cell transplant. Today, he remains in remission — and makes the most of what he and Dr. Fajgenbaum call “overtime.”

While these patients were able to be helped by Dr. Fajgenbaum after they or their doctors reached out in search of a “Hail Mary,” Every Cure is taking a different approach. Every Cure systematically searches for the best drug repurposing opportunities with the greatest potential for impact and does the work to make sure they reach every patient who can benefit from them.




SPOTLIGHTING OUR IMPACT

Every Cure has received significant media attention and recognition, which plays a crucial role in amplifying our mission and raising awareness about our work. We have been featured on the front page of **The New York Times** and profiled by **The Wall Street Journal** as well as **The New Yorker**. We have also been featured on national television programs, including **Good Morning America**, **CBS Evening News**, **CBS Mornings with Gayle King**, **Fox News**, and as a “Champion for Change” by Sanjay Gupta on **CNN**.

Dr. Fajgenbaum has also appeared on prominent podcasts, including “**Radiolab**,” “**Possible**” with Reid Hoffman and Aria Finger, “**The Shawn Ryan Show**,” “**The Checkup with Doctor Mike**,” “**Huberman Lab**,” and “**Armchair Expert**.”

A standout moment of 2025 was a **TED Talk** that Dr. Fajgenbaum delivered that shared Every Cure’s bold vision with a global audience, inspiring new communities, supporters, and partners. He was also profiled by **Humans of New York**, one of the most powerful storytelling platforms of our time, where his story resonated deeply with readers and sparked a surge of public interest in and support of our mission.



THE
WALL STREET
JOURNAL.


THE NEW YORKER
The New York Times

CNN

abc

CBS

TED



PARTNERING FOR CURES: COLLABORATIONS ACROSS GOVERNMENT, PHILANTHROPY, TECH, & BEYOND

Since Every Cure launched in 2022, we have been able to make rapid progress thanks to our close collaborations with some of the world's most visionary leaders across government, philanthropy, and tech, who recognize the urgency of our mission and the transformative power of our approach.

“I support Every Cure because it’s a brilliant idea that has consistently been validated. They’re taking full advantage of artificial intelligence, and frankly, their work may someday save the lives of my family and friends, not to mention countless others. David Fajgenbaum and his team are about as passionate and committed as one could ever hope for. Why wouldn’t someone support Every Cure?”

— Joe Deitch, founder of the Elevate Prize Foundation

Elevate Prize Founder’s Award: Recognizing bold innovation

In 2023, Dr. David Fajgenbaum received the inaugural Elevate Prize Founder’s Award, which recognized our vision to transform medicine by unlocking the full potential of existing drugs.

ARPA-H: A historic federal investment

In early 2024, in a powerful endorsement of our mission, the U.S. government’s Advanced Research Projects Agency for Health, which aims to advance high-impact biomedical and health research, awarded Every Cure a contract to develop and scale our MATRIX AI platform. This marked a significant federal commitment to advancing drug repurposing.



Dr. David Fajgenbaum joined leadership from ARPA-H to announce the ARPA-H contract at the White House in February 2024. (YouTube)



The Audacious Project announced its 2024 winning grantees, which included Every Cure with Dr. Fajgenbaum as its lead.



Dr. Fajgenbaum spoke at numerous national and international meetings like the 2024 Google Cancer AI Symposium in Boston.

The Audacious Project: Powering global change

In mid-2024, Every Cure was selected as one of the recipients of TED's Audacious Project, a prestigious philanthropic initiative that champions bold ideas for large-scale impact. This generous support helps to further our mission to identify and advance the most promising repurposing opportunities and translate them into life-changing treatments for patients all over the world.

Google: Partnering on tech

In 2025, Every Cure and Google announced an expanded collaboration to transform AI-driven drug repurposing. By leveraging Google Cloud's AI tools, including Gemini 2.0 large language models to power our MATRIX platform, we will accelerate the discovery, validation, and dissemination of live-saving repurposed treatments, thus transforming health care delivery and patient outcomes all over the world.

NUMEROUS AWARDS FOR OUR IMPACT

- 2025
 - **John Scott Award**, the nation's oldest scientific award, whose past recipients include Jonas Salk, Nikola Tesla, and Marie Curie (Dr. David Fajgenbaum)
 - **TIME, Best Inventions of 2025**
 - **TIME, TIME100 Health, List of the World's Most Influential Individuals in Health** (Dr. David Fajgenbaum)
 - **TIME, TIME100 Next, List of the World's Most Influential Rising Stars** (Dr. David Fajgenbaum)
 - **Newsweek, AI Impact Award**
- 2024
 - **TED, Audacious Project**
 - **Life Sciences Pennsylvania, Emerging Company of the Year**
 - **505(b)(2) Platform, Non-Profit of the Year**
 - **MIT, Cure Xchange Challenge: Health AI for Good**
 - **The Philadelphia Citizen, Citizen of the Year Award** (Dr. David Fajgenbaum)
 - **American Philosophical Society, Judson Daland Prize for patient-oriented clinical investigation** (Dr. David Fajgenbaum)
 - **WebMD Health Hero of the Year** (Dr. David Fajgenbaum)
 - **Sarcoma Foundation for America, Vision of Hope Award** (Dr. David Fajgenbaum)

THANK YOU FOR YOUR SUPPORT

We are deeply grateful for your generosity, which has helped propel Every Cure forward in our mission to save and improve lives by repurposing drugs. Your commitment to our mission brings us closer to a future in which every patient can access every possible cure.

Thanks to your support, we are now entering a new, pivotal phase in which AI, medicine, and patient-focused efforts are aligning to drive significant patient impact. This is only the beginning.

Together, we can prove that a broken system can be changed and millions of lives can be saved around the world. Thank you for standing with us and being a vital part of our journey. We couldn't do it without you.



LOOKING AHEAD

As we look to 2026 and beyond, Every Cure is well positioned to take significant steps forward in our mission to save and improve lives by repurposing drugs and to create a world where no patient suffers when a treatment is hiding in plain sight.

We are driven by our ambitious goal of advancing repurposed treatments to patients around the world for 15-25 diseases that have few or no options by 2030.

To achieve this, we are focused on the following strategic priorities:

- Continue to **enhance our AI platform** to uncover even more hidden drug repurposing opportunities.
- **Expand and strengthen our medical team** to accelerate the review and identification of promising drug repurposing opportunities.
- **Launch efficient laboratory studies and clinical trials** to ensure we're validating and evaluating the most promising drug repurposing opportunities as quickly and efficiently as possible.
- **Build an Impact team and a repeatable process to ensure treatments reach all patients who can benefit from them** by engaging with government bodies, regulatory agencies, payers, physicians, patient advocacy groups, disease research and patient organizations, and other experts.



At left, Dr. Fajgenbaum with Gary, diagnosed with Castleman disease. At right, Dr. Fajgenbaum with Kyle Bryant, an athlete and speaker diagnosed with Friedreich's Ataxia.

LEADERSHIP TEAM



DAVID FAJGENBAUM, MD, MBA, MSc Co-Founder and President

A physician-scientist and patient battling Castleman disease, David has transformed the treatment of patients with Castleman and advanced 14 repurposed treatments for multiple diseases. He co-founded Every Cure to unlock more hidden cures from existing drugs and has received numerous honors for his work.



MARY ZUCCATO, MBA

Chief Operating Officer

Mary is a leader in the finance and nonprofit sectors, with experience in senior management positions at CDCN and Vanguard. She has served CDCN since 2014, initially becoming involved to support David in the search for a cure for his own disease. She is dedicated to serving the broader rare disease community through biomedical research, drug repurposing, and patient support at Every Cure.



CHARLIE HEMPSTEAD, MBA

Chief Platform Officer

A leader with a proven track record of aligning brilliant scientists and engineers with ambitious goals, Charlie works with Every Cure's technology team and partners to build the data ecosystem and AI platform that power our drug repurposing predictions. Previously, she worked at QuantumBlack, McKinsey & Company's artificial intelligence arm, where she specialized in complex AI builds and MLOps in the Life Sciences field.



ALEX PAMPALONE, MPD, EdM, MBA

Chief Philanthropy Officer

Alex partners with donors to help them achieve philanthropic goals through their shared mission with Every Cure. Alex has over 15 years of development experience, having fundraised for small nonprofits and large universities and hospitals alike.



MATT GODDEERIS, PhD

Vice President of Discovery

Matt Goddeeris, PhD, leverages his expertise as a cell biologist and drug hunter to drive therapeutic innovation. With over a decade of pharma industry experience building teams around groundbreaking concepts, he advanced three novel small molecules to IND across a range therapeutic areas to treat rare disease before joining Every Cure. Since joining Every Cure, he has led a team that has reviewed over 8,000 drug repurposing opportunities and selected 9 programs for advancement.



Every Cure's team is made up of approximately 40 dedicated, passionate experts who work hard to advance the organization's mission and demonstrate an unwavering commitment to improving the lives of patients around the world.

BOARD OF DIRECTORS

Our Board of Directors brings together influential leaders from tech, health care, and other industries to provide bold insight and strategic guidance to help drive our mission forward.



DAVID FAJGENBAUM, MD, MBA, MSc
Co-Founder & President of Every Cure



GRANT W. MITCHELL, MD, MBA
Co-Founder of Every Cure



ERIC HORVITZ, MD, PhD
Chief Scientific Officer at Microsoft



ROBERT A. MCDONALD
Former CEO of Procter & Gamble and former Secretary of Veterans Affairs under President Obama



TANIA SIMONCELLI, MS
Vice President of Science in Society at the Chan Zuckerberg Initiative



JANET WOODCOCK, MD
Former Acting Commissioner of the U.S. Food and Drug Administration




JULIAN BAKER
Managing Partner of Baker Bros. Advisors



FREDA LEWIS-HALL, MD, DFAPA, MFPM
Former Executive Vice President and Chief Medical Officer at Pfizer

“I believe and am devoted to ensuring that every individual has a fair and just opportunity to attain their highest level of health. Somewhere right now, a patient is desperately waiting for the hope we already hold in our hands. Every Cure is proving that by repurposing existing drugs, we can unlock untapped power to treat illness and save lives now. This is more than innovation — it’s a movement we must all stand behind.”

— Freda Lewis-Hall,
Every Cure board member



EVERYCURE.ORG



Donate
give.everycure.org



**Submit a
Repurposing Idea**
everycure.org/ideas



Partner with Us
[everycure.org/
partnerships](http://everycure.org/partnerships)



Follow & Share
[instagram.com/
everycure](http://instagram.com/everycure)



Contact
info@everycure.org